Clinical Trials

Gastrointestinal Oncology UCSF

Thank you for your interest in GI clinical trials at UCSF.

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.

Please see the links below for current open trials at UC San Francisco.

Colorectal | Early Phase | Gastro Esophageal | Hepatocellular and Biliary Tract
Neuroendocrine | PancreaticOpening Soon | All Cancer Trials at UCSF

 

COLORECTAL

METASTATIC
 
CC#16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Contact: Curt Johanson (415) 353-2310: curt.johanson@ucsf.edu
 
CC# 159510A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer
Contact: Brittany Bianchi (415) 885-3725: Brittany.Bianchi@ucsf.edu
 
NEOADJUVANT RECTAL

Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu

CC#15451: A phase II multi center randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or non-operative management
Contact: Lillian Jahan (415) 353-7252: Lillian.Jahan2@ucsf.edu
 
ANAL
 
AMC 092: A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons (NCT02437851).
Contact: Rachel Silverstien (415) 353-7443: Rachel.Silverstein@ucsf.edu

 

EARLY PHASE

 
CC#AMC095A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Paul Couey (415)476-4082  Paul.Couey@ucsf.edu
 
CC# 149511: A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors
Contact: Jenna Zhang (415) 514-8867  Jenna.Zhang@ucsf.edu
 
CC# 15956A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed against CD47, in Subjects with Advanced Solid and Hematologic Cancers
Contact: Armand Harb (415) 353-7381  Armand.Harb@ucsf.edu
 
CC# 15958 Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies
Contact: Brittany Bianchi (415) 885-3725 Brittany.Bianchi@ucsf.edu
 
CC# 159510A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer
Contact: Brittany Bianchi (415) 885-3725 Brittany.Bianchi@ucsf.edu
 
CC# 159516A phase Ib, open-label study of alpelisib (BYL719) in combination with cisplatin in patients with HPV+ solid tumor malignancies
Contact: Armand Harb (415) 353-7381  Armand.Harb@ucsf.edu
 
CC# 159518A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
Contact: Nilson Wu (415) 353-4084  Nilson.Wu@ucsf.edu
 
CC# 159520A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
Contact: Claire Hooker  (415) 885-3724   Claire.Hooker@ucsf.edu
 
CC# 159512A Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Is Available
Contact: Emily Boyd (415) 514-6638  Emily.Boyd2@ucsf.edu
 
CC# 16955An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-like Protein 3-Expressing Advanced Solid Tumors
Contact: Emily Boyd (415) 514-6638  Emily.Boyd2@ucsf.edu
 
CC# 16954Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors
Contact: Kathleen (Katie) Comerford (415) 514-6674 Kathleen.Comerford@ucsf.edu
 
CC#169518 Phase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors
Contact: Phu Lam (415) 514-6363 Phu.Lam@ucsf.edu
 
CC#169519 A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid  Tumors
Contact: Kathleen (Katie) Comerford (415) 514-6674 Kathleen.Comerford@ucsf.edu
 

GASTRO ESOPHAGEAL

CC#164515A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 combined with Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
ContactContact:  Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
 
CC#159510 A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal Cancer
ContactContact:  Brittany Bianchi (415) 885-3725 Brittany.Bianchi@ucsf.edu
 
CC# 154515A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors
ContactSamantha Maisel (415) 476-5442: Samantha.Maisel@ucsf.edu
 
CC# 16459>A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
ContactPaige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu
 
CC# 154525A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
ContactClaire Greene (415) 514-6258: Claire.Greene@ucsf.edu
 

 

HEPATOCELLULAR AND BILIARY TRACT

 
CC# 13455: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Contact: Malori Mindo (415)502-6313: Malori.Mindo@ucsf.edu
 
CC# 154514: A Phase II Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC)
Contact: Samantha Maisel (415) 502-3310: Samantha.Maisel@ucsf.edu
CC# 154523A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma
Contact: Kelly Bauer (415) 514-4633:  Kelly.Bauer@ucsf.edu
CC# 154524A Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers
Contact: Emily Mitchell (415) 476-5442: Emily.Mitchell@ucsf.edu
CC# 16451A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremeliumumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu
CC# 16456 Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma who Progressed on or Were Intolerant to First-Line Systemic Therapy
Contact: Kelly Bauer (415) 514-4633:  Kelly.Bauer@ucsf.edu
CC#16457Protocol I3O-MC-JSBF Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
Contact: Malori Mindo (415) 502-6313:  Malori.Mindo@ucsf.edu
CC#16458 A Multicenter Phase I/II Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Contact : Paige Steiding (415) 514-6314:  Paige.Steiding@ucsf.edu
CC#15452A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Contact: Maddy Griffith (415) 476-7974:  Madeline.Griffith@ucsf.edu
CC# 164514 Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization in Hepatocellular Carincoma
Contact: Curt Johanson (415) 353-2310:  Curt.Johanson@ucsf.edu

NEUROENDOCRINE TUMORS

 
CC#14453: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Contact: Thomas Hope: Thomas.Hope@ucsf.edu
 
CC#149511A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors
Contact: Nilson Wu (415) 353-4084: Nilson.Wu@ucsf.edu
 

PANCREATIC

CC#144515: A Phase I Study of PEGPH20, Gemcitabine Plus Nab-Paclitaxel in Patients With Borderline Resectable Pancreatic Cancer
Contact: Louis Wong (415) 514-8101: Louis.Wong@ucsf.edu

CC#144525: A Phase Ib/II Safety and Efficacy Trial of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

CC#15459A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of MM-141 plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer (CARRIE)
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu

 

**************************************************

 

**TO BE OPENED WITHIN 3 MONTHS**

CC#159521: A Phase 1b, Open-label, Dose Escalation and expansion study of Demcizumab + Pembrolizumab and Demcizumab + Pembrolizumab, Pemetrexed and Carboplatin in Patients with Locally advanced or metastatic solid tumors.
Contact: Kamran Abri Lavasani (415) 353-8337  Kamran.AbriLavasani@ucsf.edu
 
CC#169517:A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
Contact: Kamran Abri Lavasani (415) 353-8337  Kamran.AbriLavasani@ucsf.edu
 
CC#17451A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
Contact: Malori Mindo (415) 502-6313:  Malori.Mindo@ucsf.edu
 
CC#17452 An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior treatment
Contact: Bryant Chee (415) 353-7145: Bryant.Chee@ucsf.edu
 
CC#164518 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Contact: Louis Wong (415) 514-8101 Louis.Wong@ucsf.edu
 
CC#17455: Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
Contact: Bryant Chee (415) 353-7145: Bryant.Chee@ucsf.edu
 
CC#17455 A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related
Contact: Maddy Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

 

For information on Phase 1 clinical trials not listed in this newsletter please contact:
Anne Reinert, NP (415) 415-353-9291: Anne.Reinert@ucsfmedctr.org